An Open, Single-Center, Single Arm Trial to Evaluate the Efficacy and Safety of Dose Escalation of Icotinib in Advanced NSCLC Patients After Routine Icotinib Therapy.

Trial Profile

An Open, Single-Center, Single Arm Trial to Evaluate the Efficacy and Safety of Dose Escalation of Icotinib in Advanced NSCLC Patients After Routine Icotinib Therapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Sep 2014

At a glance

  • Drugs Icotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Zhejiang Beta Pharma
  • Most Recent Events

    • 13 Feb 2014 Planned End Date changed from 1 Nov 2013 to 1 Feb 2014 as reported by the ClinicalTrials.gov record.
    • 13 Feb 2014 Status changed from recruiting to completed as reported by the ClinicalTrials.gov record.
    • 03 Jul 2013 Planned number of patients changed from 30 to 35 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top